AIDS
-
Randomized Controlled Trial
Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
To assess the cost-effectiveness of etravirine (INTELENCE), a novel nonnucleoside reverse transcriptase inhibitor, used in combination with a background regimen that included darunavir/ritonavir, from a Canadian Provincial Ministry of Health perspective. ⋯ When compared with optimized standard of care including darunavir/ritonavir, adding etravirine represents a cost-effective option for treatment-experienced adults in Canada.